Funding announcement
CEO, Polyactiva
Dr Russell Tait
Roles
Coverage
Stories naming Dr Russell Tait. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Funding announcement
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period
PolyActiva's glaucoma implant was well tolerated in a Phase I trial and a Phase II study is underway; the Melbourne biotech is backed by Brandon Capital's MRCF and Yuuwa Capital.
Unnamed stage
$10m
PolyActiva completes recruitment in key Phase I glaucoma implant safety study.
PolyActiva finished enrolling patients in its Phase I glaucoma implant trial and closed a AU$10 million raise from existing backers including the MRCF and Yuuwa Capital to fund further clinical studies.